Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.63 |
| ▸ | PRMT5 | O14744 | 17/20 | 0.62 |
| ▸ | WDR77 | Q9BQA1 | 16/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15824119 | 0.88 | CARM1 (0.67) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL15825243 | 0.88 | CARM1 (0.67) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL29373628 | 0.88 | CARM1 (0.67) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL29374314 | 0.88 | CARM1 (0.67) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL15823999 | 0.88 | CARM1 (0.67) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL29373636 | 0.88 | CARM1 (0.67) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL30019323 | 0.87 | CARM1 (0.74) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL17813632 | 0.83 | CARM1 (0.68) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL17578741 | 0.82 | CARM1 (0.56) | CARM1PRMT5WDR77LMNAHTT | |
| SCHEMBL21384872 | 0.82 | CARM1 (0.67) | CARM1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189042-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| EP-3189042-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD (AU) | 2020-05-12 | — | — | US | disclosed |
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD (AU) | 2020-05-12 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| WO-2016034675-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | PRMT5, PRMT3, PRMT1 | CARM1 9/4885PRMT5 1/4885WDR77 22/4885 |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT3, PRMT1 | CARM1 9/4885PRMT5 1/4885WDR77 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.